__timestamp | Amgen Inc. | GSK plc |
---|---|---|
Wednesday, January 1, 2014 | 4297000000 | 3450000000 |
Thursday, January 1, 2015 | 4070000000 | 3560000000 |
Friday, January 1, 2016 | 3840000000 | 3628000000 |
Sunday, January 1, 2017 | 3562000000 | 4476000000 |
Monday, January 1, 2018 | 3737000000 | 3893000000 |
Tuesday, January 1, 2019 | 4116000000 | 4568000000 |
Wednesday, January 1, 2020 | 4207000000 | 5098000000 |
Friday, January 1, 2021 | 4819000000 | 5278000000 |
Saturday, January 1, 2022 | 4434000000 | 5488000000 |
Sunday, January 1, 2023 | 4784000000 | 6223000000 |
Monday, January 1, 2024 | 5964000000 |
In pursuit of knowledge
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and GSK plc have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, GSK plc's R&D expenses surged by approximately 80%, peaking in 2023 with a 6.2 billion USD investment. This reflects GSK's aggressive push towards expanding its research capabilities and product pipeline.
Conversely, Amgen Inc. maintained a more stable R&D expenditure, with a modest increase of around 11% over the same period. Their highest investment was recorded in 2021, with a 4.8 billion USD allocation. This steady approach underscores Amgen's focus on optimizing existing research avenues while cautiously exploring new opportunities. As these giants continue to innovate, their R&D strategies will undoubtedly shape the future of healthcare.
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
R&D Insights: How Amgen Inc. and Pharming Group N.V. Allocate Funds
Research and Development Expenses Breakdown: Amgen Inc. vs Soleno Therapeutics, Inc.
Comparing Innovation Spending: Amgen Inc. and Ligand Pharmaceuticals Incorporated
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: GSK plc vs Neurocrine Biosciences, Inc.
R&D Spending Showdown: GSK plc vs Insmed Incorporated
R&D Insights: How GSK plc and Ascendis Pharma A/S Allocate Funds
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
GSK plc vs PTC Therapeutics, Inc.: Strategic Focus on R&D Spending